Get Well Soon
  • Innovation
  • About Us

300,000+ clinical trials. Find the right one.

1 active trial for Refractory Childhood Hodgkin Lymphoma

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing (DST). In addition, genetic information will be obtained from cancer and normal (germline) tissue and correlated with drug response. This study will provide the platform for informing treating physician about individualized treatment options. The main outcome of this study will be the proportions of the patients whose treatment was guided by the personalized medicine approach.

Start: February 2019
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2022